Call Spread on JAZZ on 11/5/2014

Jazz Pharmaceuticals Company (JAZZ) is a specialty biopharmaceutical company.

The firm identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally.

Its products comprise Xyrem for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment and prevention of VOD, a potentially life-threatening complication of HSCT; Prialt for the management of severe chronic pain; and FazaClo LD and FazaClo HD tablets for the treatment-resistant schizophrenia, as well as Versacloz for treatment-resistant schizophrenia.

The company also develops JZP-110, an investigational compound, which is in clinical development for the treatment of EDS in patients with narcolepsy; and JZP-386, a deuterium-modified analog of sodium oxybate products that is under pre-clinical research and development and is intended for the treatment of narcolepsy patients.

In addition, it offers products in the areas of hematology and oncology drugs, such as Asparec, which is in Phase I clinical trial for the treatment of patients with ALL with E.coli asparaginase hypersensitivity; Defibrotide for the treatment of severe VOD; and Leukotac, an anti-CD25 monoclonal antibody that is in Phase III clinical trials and is intended for the treatment of steroid-refractory acute GvHD.

Shares are heading higher in an "upward trading channel." 

52-Week Trading Range: $90.48 - $176.60

Last Trade: $168.48

Trade Buy 1 December $170.00 Call at $10.30 Sell 1 December $180.00 Call at $5.30 For a net debit of $5.00 Profit/Loss Analysis Breakeven at $175.00 Maximum profit is $500.00 at strike of $180.00 Maximum loss is ($500.00) at strike of $170.00 Closing Summary Sold 1 December $170.00 Call at $13.00 Bought 1 December $180.00 Call at $6.00

Position closed on 12/4/2014 at price of $7.00 with a 40.00% gain in 29 days.

Updates

12/4/2014 1:35:08 PM

We are taking profits on JAZZ Call Spread. 

Back to Portfolio